For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Senior Research Executives from Boehringer Ingelheim and The Garvan Institute to Present at Pharmaxis Investor Research Briefing
Pharmaceutical research company Pharmaxis (ASX: PXS) advises that it will host an investor research briefing on Tuesday, 20 November from 10am to 12.00pm (AEDT) that will feature presentations by a Boehringer Ingelheim global project manager and a research leader from the Garvan Institute of Medical Research. The event will also provide an overview of the Pharmaxis drug discovery pipeline including the anti-inflammatory drug currently being developed by Boehringer Ingelheim, work in collaboration with the Garvan Institute of Medical Research on an anti-fibrotic LOX inhibitor targeting pancreatic cancer and the anti-fibrotic LOXL2 inhibitor program currently completing phase 1 trials and extended toxicity studies.
This is a unique opportunity to hear directly from the Pharmaxis executive research team along with the perspectives of a committed pharmaceutical partner and a leading medical research institute.
Attendance at this event is by invitation only. A live webcast will be accessible to all investors via the homepage of the Pharmaxis website at www.pharmaxis.com.au and will be available for replay after the event.
Pharmaceutical company Pharmaxis (ASX: PXS) today announced positive results from the Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).
The double-blind placebo controlled study consisted of two stages. The first single ascending dose stage was conducted in 48 healthy subjects divided into six groups with each taking a single dose ranging from 10mg to 400mg or placebo. The second multiple ascending dose stage was conducted in 24 healthy subjects divided into three groups which each received a single daily dose ranging from 100mg to 400mg or placebo for 14 days.
The excellent drug like properties demonstrated in earlier pre-clinical testing were confirmed. There were no adverse safety findings in either the first or second stages of the study and the pharmacokinetic profile showed the expected dose related increases in exposure.
In addition to studying the safety and pharmacokinetic profile, the clinical trial also investigated the degree to which the drug can inhibit the target enzyme LOXL2 which is implicated in several different fibrotic diseases. Importantly, Pharmaxis has been able to demonstrate a large and highly significant inhibition of this enzyme in blood serum for a full 24 hours from a single dose and that daily dosing over a 14-day period now meets our targeted effect of greater than 80% inhibition at the 400mg dose.Read full media release - pdf
Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that its non-executive director Dr Simon Buckingham will retire at the conclusion of his current term at the 2018 annual general meeting, to be held on 22 November 2018.Read full media release - pdf